Skip to main content
Clinical Trials/NCT03748511
NCT03748511
Terminated
Not Applicable

Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease

HaEmek Medical Center, Israel1 site in 1 country62 target enrollmentMarch 5, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients With Fatty Liver Disease
Sponsor
HaEmek Medical Center, Israel
Enrollment
62
Locations
1
Primary Endpoint
Transient Elastography Test
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

This study investigates the relation between the gastrointestinal tract bacteria and the progression of fatty liver disease .

Detailed Description

In the gastrointestinal (GI) tract live wide spectrum of bacteria, in this study we are trying to find if there is a relation between the GI tract bacteria and the development of non alcoholic fatty liver disease, the results of the this study may help us identify the stage of liver disease in noninvasive means and enables us to adopt methods to reduce morbodity.

Registry
clinicaltrials.gov
Start Date
March 5, 2019
End Date
September 8, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rawi Hazzan

Head of Liver Unit

HaEmek Medical Center, Israel

Eligibility Criteria

Inclusion Criteria

  • patients with non alcoholic fatty liver disese.
  • patients who give approval to participate in the study

Exclusion Criteria

  • liver failure
  • acute or chronic kidney failure
  • heart failure ( NYHA 3-4)
  • active cancer
  • fatty liver due to non alcoholic etiology.
  • patients who consume drugs from the estrogen/methotrexate family, or chloroquine.
  • history of hypothyrodism or cushing.
  • patients who used TPA in the last 6 months .
  • pathients with chronic liver disease like A1AT, hemochromatosis, wilson, toxic damage and autoimmunity .
  • special population like - children, pregnant women and patients who lack the ability to make judgment.

Outcomes

Primary Outcomes

Transient Elastography Test

Time Frame: up to 2 hours

Ultrasound Elastography is a non-invasive test which uses the technology of Shear Wave Elastography (SWE) obtained from the right liver lobe for staging liver fibrosis according to Metavir Fibrosis Score . Metavir Fibrosis Score is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy. Liver fibrosis assessed by Shear Wave Elastography is well correlated to biopsy using Metavir Score. The outcome of the test will be correlated to Metavir Score system according to the chart below: SWE (kiloPascal) , METAVIR score, Fibrosis Level. Below 5 , F0 , No fibrosis. 5.0-7.1 , F1 , Mild Fibrosis. 7.1-8.7 , F2 , Significant Fibrosis. 8.7-10.4 , F3 , Sever Fibrosis . 10.4-19 , F4 , Cirrhosis.

Secondary Outcomes

  • Gastrointestinal Microbiome test(up to 1 month)

Study Sites (1)

Loading locations...

Similar Trials